• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Radicava (edaravone)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Radicava (edaravone)

  • Profile

Profile

Contact Information

Contact: Mitsubishi Tanabe Pharma America
Website: www.radicava.com

Currently Enrolling Trials

    Show More

    General Information

    Radicava (edaravone) is a free radical scavenger.

    Radicava is specifically indicated for the treatment of amyotrophic lateral sclerosis (ALS). 

    Radicava is supplied as an infusion for intravenous administration and as an oral suspension (Radicava ORS).

    • The recommended dosage of Radicava is an intravenous infusion of 60 mg administered over a 60-minute period.
    • The recommended dose of Radicava ORS is 105 mg (5 mL) taken orally or via feeding tube in the morning after overnight fasting. Food should not be consumed for 1 hour after administration except water. 

    Both formulations should be administered according to the following schedule: 

    • An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period
    • Subsequent  treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods

    Mechanism of Action

    Radicava (edaravone) is a free radical scavenger. It is believed to relieve effects of oxidative stress, a likely key factor in the onset and progression of ALS. Oxidative stress is thought to be an imbalance between the production of free radicals (unpaired, reactive electrons) and the ability of the body to counteract or detoxify their harmful effects. In patients with ALS, there are consistent increases in oxidative stress biomarkers.

    Side Effects

    Adverse effects associated with the use of Radicava may include, but are not limited to, the following:

    • contusion
    • gait disturbance
    • headache

    Clinical Trial Results

    The FDA approval of Radicava was based on a 6-month, randomized, placebo controlled, double-blind study conducted in Japanese patients with ALS who were living independently and met the following criteria at screening: 

    • Functionality retained most activities of daily living (defined as scores of 2 points or better on each individual item of the ALS Functional Rating Scale – Revised [ALSFRS-R; described below])
    • Normal respiratory function (defined as percent-predicted forced vital capacity values of [%FVC] ≥ 80%)
    • Definite or Probable ALS based on El Escorial revised criteria
    • Disease duration of 2 years or less 

    The study enrolled 69 patients in the Radicava arm and 68 in the placebo arm. Radicava was administered as an intravenous infusion of 60 mg given over a 60 minute period according to the following schedule:  An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period (Cycle 1). Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (Cycles 2-6). The primary efficacy endpoint was a comparison of the change between treatment arms in the ALSFRS-R total scores from baseline to Week 24. Data demonstrated patients who received Radicava for six months experienced significantly less decline in physical function—by 33 percent. 

    Approval Date: 2017-05-01
    Company Name: Mitsubishi Tanabe Pharma America
    Back to Listings

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing